Coagulopathy in Childhood Acute Lymphoblastic Leukaemia
Launched by KAROLINSKA UNIVERSITY HOSPITAL · Feb 2, 2024
Trial Information
Current as of November 13, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how blood clotting works in children diagnosed with Acute Lymphoblastic Leukemia (ALL), a type of cancer that affects the blood and bone marrow. Researchers want to learn more about the balance between bleeding and clotting during the early treatment phase, especially while using certain medications like steroids and asparaginase. The goal is to find out if certain proteins in the blood can help predict problems like blood clots or bleeding. Understanding these factors could help doctors manage and reduce complications related to blood issues in children undergoing treatment for ALL.
To participate in this study, children aged 1 to 17 who have been diagnosed with ALL in Sweden and are starting treatment according to a specific protocol may be eligible. Parents will need to give their consent, and kids over 12 will also have the option to agree to participate. The study is set to include about 100 young patients across several hospitals in Sweden. While the trial is not yet recruiting, it aims to provide valuable insights that could improve the care and outcomes for children facing this challenging illness.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Diagnosis of Acute Lymphoblastic Leukaemia (ALL) in Sweden
- • Age 1-17.99 years at diagnosis
- • Planned/Initiated treatment for ALL according to the ALLTogether1 protocol
- • Signed informed consent from parents and patients (from 12 years - voluntary if \<15 years)
- Exclusion Criteria:
- • Other underlying diseases which according to examiner's clinical assessment may increase the risk of bleeding or thrombosis and which are expected to lead to adaption of the therapy protocol for ALL (e g APS, moderate/severe v Willebrand disease, haemophilia)
- • Patient not treated according to the ALLTogether1 protocol (including patients with BCR::ABL1, mixed phenotype acute leukaemia - MPAL)
About Karolinska University Hospital
Karolinska University Hospital is a leading academic medical center in Sweden, renowned for its commitment to advanced healthcare research and innovative clinical practices. As a key sponsor of clinical trials, the hospital leverages its extensive expertise in medical research and collaboration with Karolinska Institutet, one of the world's foremost medical universities. The institution is dedicated to enhancing patient care through rigorous scientific investigation, focusing on a wide range of therapeutic areas. With a multidisciplinary approach and a strong emphasis on translational medicine, Karolinska University Hospital aims to bridge the gap between laboratory findings and clinical application, ultimately striving to improve health outcomes and advance medical knowledge.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported